Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Equity Ratio (2018 - 2025)

Silence Therapeutics' Equity Ratio history spans 8 years, with the latest figure at 0.47 for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 28.33% to 0.47 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.47, a 28.33% decrease, with the full-year FY2025 number at 0.47, down 28.33% from a year prior.
  • Equity Ratio hit 0.47 in Q4 2025 for Silence Therapeutics, down from 0.5 in the prior quarter.
  • Over the last five years, Equity Ratio for SLN hit a ceiling of 0.66 in Q4 2024 and a floor of 0.09 in Q4 2021.
  • Historically, Equity Ratio has averaged 0.42 across 5 years, with a median of 0.5 in 2025.
  • Biggest five-year swings in Equity Ratio: surged 352.81% in 2024 and later fell 28.33% in 2025.
  • Tracing SLN's Equity Ratio over 5 years: stood at 0.09 in 2021, then skyrocketed by 131.65% to 0.21 in 2022, then decreased by 11.49% to 0.18 in 2023, then skyrocketed by 263.95% to 0.66 in 2024, then fell by 28.33% to 0.47 in 2025.
  • Business Quant data shows Equity Ratio for SLN at 0.47 in Q4 2025, 0.5 in Q3 2025, and 0.57 in Q2 2025.